vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$13.13 USD
-0.22 (-1.65%)
Updated Sep 27, 2024 02:23 PM ET
After-Market: $13.86 +0.73 (5.56%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for vTv Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 12 | 13 | 6 | 2 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 12 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 3 | 2 | 1 | 1 |
Total Current Assets | 11 | 27 | 16 | 7 | 3 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 6 | 9 | 7 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 3 |
Total Assets | 11 | 33 | 25 | 15 | 9 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 6 |
Accounts Payable | 10 | 7 | 8 | 6 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 11 | 8 | 9 | 6 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 19 | 19 | 1 | 3 | 3 |
Minority Interest (Liabilities) | 6 | 17 | 25 | 84 | 40 |
Total Liabilities | 36 | 44 | 35 | 95 | 58 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 1 | 1 | 1 | 1 |
Capital Surplus | 256 | 254 | 238 | 209 | 184 |
Retained Earnings | -281 | -266 | -249 | -290 | -234 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -25 | -11 | -10 | -80 | -49 |
Total Liabilities & Shareholder's Equity | 11 | 33 | 25 | 15 | 9 |
Total Common Equity | -25 | -11 | -10 | -80 | -49 |
Shares Outstanding | 2.60 | 2.60 | 2.20 | 1.90 | 1.60 |
Book Value Per Share | -9.49 | -4.13 | -4.43 | -42.16 | -30.64 |
Fiscal Year End for vTv Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 46 | 52 | 9 | 8 | 13 |
Receivables | 0 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 2 | 1 |
Total Current Assets | 46 | 54 | 11 | 10 | 14 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 4 | 8 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 46 | 54 | 11 | 15 | 22 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 9 | 10 | 10 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 7 | 9 | 11 | 10 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 19 | 19 | 19 | 19 | |
Minority Interest (Liabilities) | 0 | 0 | 6 | 11 | 19 |
Total Liabilities | 26 | 28 | 36 | 40 | 48 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 1 | 1 |
Capital Surplus | 308 | 307 | 256 | 255 | 254 |
Retained Earnings | -291 | -286 | -281 | -281 | -281 |
Other Equity | 4 | 5 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 26 | -25 | -25 | -25 |
Total Liabilities & Shareholder's Equity | 46 | 54 | 11 | 15 | 22 |
Total Common Equity | 20 | 26 | -25 | -25 | -25 |
Shares Outstanding | 3.00 | 3.00 | 2.60 | 2.60 | 2.60 |
Book Value Per Share | 6.81 | 8.66 | -9.49 | -9.70 | -9.72 |